Read by QxMD icon Read

Survival rates for distant organ metastasis in esophageal cancer patients

T Makino, M Yamasaki, Y Miyazaki, N Wada, T Takahashi, Y Kurokawa, K Nakajima, S Takiguchi, M Mori, Y Doki
Although no consensus is available on the treatment of esophageal squamous cell carcinoma (ESCC) invading adjacent organs (T4), establishing effective induction treatments is crucial to altering an unresectable status and achieving curative resection. Here, we evaluated the efficacy of chemotherapy using 5-fluorouracil, cisplatin, and docetaxel (DCF) as the initial induction treatment for T4 ESCC. Fifty patients without distant metastasis who underwent initial induction chemotherapy using DCF for T4 ESCC were propensity score-matched with 50 patients who underwent radiotherapy concurrent with cisplatin and 5-fluorouracil (CRT)...
November 28, 2017: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
Makoto Sohda, Yuji Kumakura, Hideyuki Saito, Kengo Kuriyama, Tomonori Yoshida, Hiroaki Honjyo, Keigo Hara, Daigo Ozawa, Shigemasa Suzuki, Naritaka Tanaka, Makoto Sakai, Tatsuya Miyazaki, Minoru Fukuchi, Hiroyuki Kuwano
BACKGROUND/AIM: Definitive chemoradiotherapy (CRT) without planned surgery has been recently widely used as a therapeutic option for locally advanced esophageal cancer. Salvage esophagectomy can offer the chance of prolonged survival for patients who have locoregional failure after definitive CRT, but many clinicians oppose the use of surgery due to the associated excessive morbidity and mortality. The aim of this study was to identify patients who are good candidates for salvage surgery by investigating factors influencing long-term survival...
September 2017: Anticancer Research
ShengFa Su, Tao Li, Bing Lu, XiaoHu Wang, JianCheng Li, Ming Chen, You Lu, YuJu Bai, YinXiang Hu, WeiWei Ouyang, Zhu Ma, QingSong Li, HuiQin Li, Yu Wang
PURPOSE: The aim of this prospective multi-institutional phase 2 study was to investigate disease control, survival outcomes, and toxicity after thoracic three-dimensional radiation therapy (3D-RT) with concurrent chemotherapy for newly diagnosed stage IV non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: Eligible patients were 18 to 80 years of age, had a Karnofsky performance status (KPS) score ≥70%, and newly diagnosed stage IV NSCLC with limited metastatic disease (defined as involving ≤3 organs)...
November 15, 2015: International Journal of Radiation Oncology, Biology, Physics
Yuji Murakami, Ippei Takahashi, Ikuno Nishibuchi, Yoshiko Doi, Tomoyuki Okabe, Masahiro Kenjo, Tomoki Kimura, Yasushi Nagata
BACKGROUND: The long-term outcomes of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer without regional and distant metastasis were retrospectively analyzed. METHODS: Patients with histologically confirmed esophageal submucosal cancers without regional and distant metastasis who received definitive concurrent chemoradiotherapy from 2001 to 2011 were included. Radiation therapy of a median total dose of 60 Gy/30 fractions (range, 54-66 Gy) with elective nodal irradiation of 40 Gy was combined concurrently with 5-furuorouracil-based chemotherapy...
October 2015: International Journal of Clinical Oncology
Ming-Qiu Chen, Ben-Hua Xu, Ying-Ying Zhang
BACKGROUND: Esophageal cancer is the eighth most common malignancy and sixth most fatal disease worldwide. However, it is the fourth most common cause of death in China. Although surgery is currently the recommended course of treatment, there are some patients that do not receive radical treatment due to the presence of distant organ or lymph node metastasis. There is at present no established treatment standard for esophageal cancer patients with distant organ metastasis. The purpose of this study was to investigate the prognostic factors involved in determining survival of esophageal cancer patients with distant organ metastasis at initial diagnosis, and to provide a reference for the planning of a clinical treatment strategy...
November 2014: Journal of the Chinese Medical Association: JCMA
Sarah McAvoy, Katherine Ciura, Caimiao Wei, Justin Rineer, Zhongxing Liao, Joe Y Chang, Matthew B Palmer, James D Cox, Ritsuko Komaki, Daniel R Gomez
PURPOSE: Intrathoracic recurrence of non-small cell lung cancer (NSCLC) after initial treatment remains a dominant cause of death. We report our experience using proton beam therapy and intensity modulated radiation therapy for reirradiation in such cases, focusing on patterns of failure, criteria for patient selection, and predictors of toxicity. METHODS AND MATERIALS: A total of 102 patients underwent reirradiation for intrathoracic recurrent NSCLC at a single institution...
November 15, 2014: International Journal of Radiation Oncology, Biology, Physics
Shaohua Wang, Yuji Tachimori, Nobukazu Hokamura, Hiroyasu Igaki, Takayoshi Kishino, Ryoji Kushima
BACKGROUND: We summarize the experience of diagnosis and surgical therapy for primary malignant melanoma of the esophagus (PMME). METHODS: Clinical data of 13 patients diagnosed as having PMME treated by surgery as their primary therapy from 2000 to 2012 were retrospectively analyzed, and survival information was collected through follow-up. RESULTS: The average age (±standard deviation) of participants in this study was 66.4±7.6 years, and 84...
September 2013: Annals of Thoracic Surgery
Ritsuko Komaki, Xiong Wei, Pamela K Allen, Zhongxing Liao, Luka Milas, James D Cox, Michael S O'Reilly, Joe Y Chang, Mary Frances McAleer, Melenda Jeter, George R Blumenschein, Merrill S Kies
PURPOSE: Preclinical findings suggest that adding targeted therapies to combination radiation-chemotherapy can enhance treatment efficacy; however, this approach may enhance normal tissue toxicity. We investigated the maximum tolerated dose, dose-limiting toxicities, and response rate when the selective cyclooxygenase-2 inhibitor celecoxib is added to concurrent irinotecan, cisplatin, and radiation therapy for patients with inoperable stage II-III non-small cell lung cancer (NSCLC). METHODS AND MATERIALS: Eighteen patients were analyzed in a phase I clinical dose-escalation trial...
2011: Frontiers in Oncology
Michael T Milano, Alan W Katz, Hong Zhang, Paul Okunieff
PURPOSE: To analyze the long-term survival and tumor control outcomes after stereotactic body radiotherapy (SBRT) for metastases limited in number and extent. METHODS AND MATERIALS: We prospectively analyzed the long-term overall survival (OS) and cancer control outcomes of 121 patients with five or fewer clinically detectable metastases, from any primary site, metastatic to one to three organ sites, and treated with SBRT. Freedom from widespread distant metastasis (FFDM) was defined as metastatic disease not amenable to local therapy (i...
July 1, 2012: International Journal of Radiation Oncology, Biology, Physics
Yoshiaki Osaka, Motoo Shinohara, Sumito Hoshino, Takashi Ogata, Yu Takagi, Akihiko Tsuchida, Tatsuya Aoki
Advanced esophageal cancer with widespread metastasis to lymph nodes or other organs is difficult to treat and has an extremely poor prognosis. A new combined chemotherapy of docetaxel with cisplatin (CDDP) and 5-fluorouracil (5-FU) (DPF therapy) was performed and its efficacy and safety were examined. Among those hospitalized between May 2003 and October 2009, 30 patients with stage III or stage IV unresectable, untreated advanced esophageal squamous cell carcinoma which had invaded other organs were enrolled in this study...
February 2011: Anticancer Research
K Maruyama, S Motoyama, A Anbai, S Usami, Y Sato, K Shibuya, K Yoshino, T Nakatsu, Y Minamiya, J-I Ogawa
We investigated the effectiveness of chemoradiotherapy for the treatment of lymph node recurrence and hematogenous metastasis after esophagectomy for esophageal squamous cell carcinoma. Between 2001 and 2006, 216 patients with thoracic esophageal squamous cell carcinoma had curative esophagectomy. Of those, 23 with lymph node recurrence received chemoradiotherapy (50.0-68.8 Gy). In addition, five patients had isolated recurrences in a distant organ and received chemoradiotherapy (50.0-60.0 Gy). We analyzed outcomes from the radiotherapy for recurrent esophageal cancer...
April 2011: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
Naohiro Nishida, Koshi Mimori, Takehiko Yokobori, Tomoya Sudo, Fumiaki Tanaka, Kohei Shibata, Hideshi Ishii, Yuichiro Doki, Masaki Mori
BACKGROUND: FOXC2 has been implicated in cancer progression through its induction of epithelial-to-mesenchymal transition. We analyzed the clinical significance of FOXC2 in esophageal cancer cases, in which early distant metastasis or invasion to nearby organs is an obstacle to treatment. METHODS: Quantitative reverse transcriptase-polymerase chain reaction was used to evaluate FOXC2 mRNA expression in 70 esophageal cancer cases to determine the clinicopathologic significance of FOXC2 expression...
February 2011: Annals of Surgical Oncology
T Tanaka, H Fujita, S Matono, T Nagano, K Nishimura, K Murata, K Shirouzu, G Suzuki, N Hayabuchi, H Yamana
Esophageal cancer patients with distant organ metastasis have usually been treated only to palliate symptoms without multimodality therapy. The current study evaluates the role of multimodality therapy in esophageal squamous cell cancer patients with distant organ metastasis. Between February 1988 and January 2007, 80 esophageal squamous cell cancer patients with distant organ metastases were treated at our institution. Multimodality therapy was performed in 58 patients: 43 patients received chemoradiotherapy, 13 underwent surgery followed by chemotherapy and/or radiation therapy, and two received chemotherapy or chemoradiotherapy followed by surgery...
November 2010: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
A Eroglu, A Turkyilmaz, M Subasi, N Karaoglanoglu
Most patients with esophageal carcinoma present in the advanced stage die from tumor invasion and widespread metastases. Because radical regimens are not appropriate for the majority of patients, and their expected survivals are as short as to be measured by months, the main aim of therapy is palliation with minimum morbidity and mortality. Among the palliative modalities are surgery, external radiotherapy or brachytherapy, dilatation, laser, photodynamic therapy, bipolar electrocoagulation tumor probe, and chemical ablation...
January 2010: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
Mark J Krasna
Oesophageal and gastric cancers are amongst the most frequent and lethal of cancers worldwide. In the US alone, some 13 000 individuals are affected each year, and mortality is particularly high in elderly patients with advanced stage disease and multiple co-morbidities. Patients usually do not present until later in the disease when symptoms occur, once the tumour is sufficiently large to cause obstruction or invasion of adjacent structures. Oesophageal cancer can metastasize to almost any organ, and widespread distant metastases are almost always present at the time of death...
2009: Drugs & Aging
Mitsuo Tachibana, Noriyuki Hirahara, Shoichi Kinugasa, Hiroshi Yoshimura
BACKGROUND: The depth of tumor penetration is a crucial factor in determining the prognosis of patients with esophageal carcinoma. Patients with superficial esophageal carcinoma (SEC) have a far more favorable clinical course compared with those with advanced cancers. The outcome for patients with mucosal cancer is excellent with a 5-year survival rate exceeding 80%. On the other hand, submucosal cancer often metastasizes to regional and/or distant lymph nodes or other organs, and the prognosis of these patients are far from satisfactory...
January 2008: Annals of Surgical Oncology
Shuhei Komatsu, Yuji Ueda, Daisuke Ichikawa, Hitoshi Fujiwara, Kazuma Okamoto, Shojiro Kikuchi, Atsushi Shiozaki, Kenichiro Imura, Rumi Ohsawa, Toshiya Ochiai, Takuji Tsubokura, Hisakazu Yamagishi
Axillary lymph node metastasis (ALNM) from esophageal cancer is rare. Its prognosis and effective treatments remain unknown. Between 1997 and 2005, esophagectomy was performed in 361 patients with esophageal cancer in our hospital. ALNM was identified in four patients (1.1%). All patients had left ALNM with ipsilateral left supraclavicular lymph node metastasis. In two patients ALNM developed after radical esophagectomy with regional lymphadenectomy and in the other two patients after chemoradiotherapy of primary lesions...
April 2007: Japanese Journal of Clinical Oncology
Takeshi Kodaira, Nobukazu Fuwa, Minoru Kamata, Kazuhisa Furutani, Hiroyuki Tachibana, Takuya Yamazaki
AIM: To assess the efficacy and feasibility of alternating chemoradiotherapy for esophageal cancer. MATERIALS AND METHODS: Patients, with previously untreated esophageal cancer, Eastern Cooperative Oncology Group performance status of 0 to 2, age 20 to 75 years and sufficient organ function, were eligible for this study. Three cycles of systemic chemotherapy with the continuous infusion of 3500 mg/m2 of 5-fluorouracil (5-FU: days 1-5) and a 6-h infusion of nedaplatin (NDP; day 6: 120-140 mg/m2), were accompanied by thoracic irradiation of 63 Gy in 35 fractions over 7 weeks...
January 2006: Anticancer Research
M Yano, K Takachi, Y Doki, I Miyashiro, K Kishi, S Noura, H Eguchi, T Yamada, M Ohue, H Ohigashi, Y Sasaki, O Ishikawa, T Matsunaga, S Imaoka
Patients with esophageal cancer often display relapse at cervical nodes after surgery, but their prognosis and a suitable therapy remains unknown. We retrospectively reviewed the records for 35 patients who underwent esophagectomy with lymphadenectomy who then displayed relapse at the cervical lymph nodes alone between 1985 and 2003 in order to observe the prognostic factors for such patients. Median survival time from the date of recurrence for all 35 patients was 12 months with 1-year, 2-year, 3-year and 5-year survival rate of 47...
2006: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
Yuichiro Doki, Osamu Ishikawa, Ko Takachi, Isao Miyashiro, Yo Sasaki, Hiroaki Ohigashi, Kohei Murata, Terumasa Yamada, Shingo Noura, Hidetoshi Eguchi, Toshiyuki Kabuto, Shingi Imaoka
The site of surgical failure in cases of thoracic esophageal cancer (TEC) may be affected by the vertical location of the cancer in this longitudinal organ, suggesting the need to select the mode of adjuvant therapy based on location. We classified 501 TECs (92% squamous cell carcinomas) that underwent curative surgery without preoperative treatment as 13% upper thoracic (Ut), 51% middle thoracic (Mt), and 36% lower thoracic (Lt) lesions. Recurrent disease was discovered in 180 (36%) of the patients during a postoperative survey, most frequently in the cervical nodes (19%), liver (18%), abdominal paraaortic nodes (17%), and upper mediastinal nodes (17%)...
June 2005: World Journal of Surgery
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"